Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Vonoprazan-based Dual and Quadruple Regimens for H. pylori Eradication
NCT06723197Phase 4Recruiting
- Sponsor
- Shandong University
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (3 arms), sponsored by Shandong University. Primary endpoint: Eradication rate of Helicobacter pylori. Started Dec 2024; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06723197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723197.